225 related articles for article (PubMed ID: 33661366)
21. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.
Amitai I; Rozovski U; El-Saleh R; Shimony S; Shepshelovich D; Rozen-Zvi B; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2020 Oct; 38(4):584-588. PubMed ID: 32506594
[TBL] [Abstract][Full Text] [Related]
22. Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX).
Cohen IJ
Med Hypotheses; 2013 Nov; 81(5):942-7. PubMed ID: 24035689
[TBL] [Abstract][Full Text] [Related]
23. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
24. [High dose methotrexate with leucovorin rescue in the treatment of malignant lymphoma].
Sampi K; Hattori M
Gan To Kagaku Ryoho; 1982 Jul; 9(6):1068-73. PubMed ID: 6985194
[TBL] [Abstract][Full Text] [Related]
25. Management of Patients with Acute Methotrexate Nephrotoxicity with High-Dose Leucovorin.
Flombaum CD; Liu D; Yan SQ; Chan A; Mathew S; Meyers PA; Glezerman IG; Muthukumar T
Pharmacotherapy; 2018 Jul; 38(7):714-724. PubMed ID: 29863765
[TBL] [Abstract][Full Text] [Related]
26. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
27. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity.
Frei E; Blum RH; Pitman SW; Kirkwood JM; Henderson IC; Skarin AT; Mayer RJ; Bast RC; Garnick MB; Parker LM; Canellos GP
Am J Med; 1980 Mar; 68(3):370-6. PubMed ID: 6965819
[TBL] [Abstract][Full Text] [Related]
28. High-dose methotrexate: a critical reappraisal.
Ackland SP; Schilsky RL
J Clin Oncol; 1987 Dec; 5(12):2017-31. PubMed ID: 3316519
[TBL] [Abstract][Full Text] [Related]
29. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
30. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
Pitman SW; Frei E
Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
[TBL] [Abstract][Full Text] [Related]
31. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for predicting high dose methotrexate associated acute kidney injury in children with acute lymphoblastic leukemia.
Li H; Xu Q; Wang Y; Chen K; Li J
Cancer Chemother Pharmacol; 2020 Jan; 85(1):95-103. PubMed ID: 31676986
[TBL] [Abstract][Full Text] [Related]
32. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?
Sterba J; Valík D; Bajciová V; Kadlecová V; Gregorová V; Mendelová D
Neoplasma; 2005; 52(6):456-63. PubMed ID: 16284689
[TBL] [Abstract][Full Text] [Related]
33. Methotrexate-leucovorin factor rescue regimens in diffuse large cell lymphoma.
Skarin AT; Canellos GP
NCI Monogr; 1987; (5):71-6. PubMed ID: 3501548
[TBL] [Abstract][Full Text] [Related]
34. High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes.
Beh SC; Kildebeck E; Narayan R; Desena A; Schell D; Rowe ES; Rowe V; Burns D; Whitworth L; Frohman TC; Greenberg B; Frohman EM
J Neurol Sci; 2017 Jan; 372():187-195. PubMed ID: 28017209
[TBL] [Abstract][Full Text] [Related]
35. Outpatient administration of high-dose methotrexate in adults without drug monitoring - a case-control study of risk factors for acute kidney injury.
Alves C; Pereira J; Rego EM; Rocha V; Silva WF
Hematol Transfus Cell Ther; 2023 Dec; ():. PubMed ID: 38233304
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function.
Barreto JN; Reid JM; Thompson CA; Mara KC; Rule AD; Kashani KB; Leung N; Larson TR; McGovern RM; Witzig TE; Barreto EF
Clin Transl Sci; 2022 Jan; 15(1):105-117. PubMed ID: 34378331
[TBL] [Abstract][Full Text] [Related]
37. The safety of administration of massive doses of methotrexate (50 g) with equimolar citrovorum factor rescue in adult patients.
Reggev A; Djerassi I
Cancer; 1988 Jun; 61(12):2423-8. PubMed ID: 3259154
[TBL] [Abstract][Full Text] [Related]
38. Leucovorin (folinic acid) rescue for high-dose methotrexate: A review.
Jiang R; Mei S; Zhao Z
J Clin Pharm Ther; 2022 Sep; 47(9):1452-1460. PubMed ID: 35929573
[TBL] [Abstract][Full Text] [Related]
39. Understanding and managing methotrexate nephrotoxicity.
Widemann BC; Adamson PC
Oncologist; 2006 Jun; 11(6):694-703. PubMed ID: 16794248
[TBL] [Abstract][Full Text] [Related]
40. Body Surface Area Dosing of High-Dose Methotrexate Should Be Reconsidered, Particularly in Overweight, Adult Patients.
Gallais F; Oberic L; Faguer S; Tavitian S; Lafont T; Marsili S; Brice A; Chatelut E; Puisset F
Ther Drug Monit; 2021 Jun; 43(3):408-415. PubMed ID: 32925658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
